Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2020-10-29 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 29, 2020, by Moleculin Biotech, Inc. It announces a press release regarding additional collaboration on a drug candidate targeting COVID-19. The document includes a press release as Exhibit 99.1 and explicitly states that the information is being furnished and shall not be deemed "filed" for purposes of the Exchange Act. The document is short (3760 characters) and primarily serves as an announcement of a press release rather than containing substantive financial data or detailed report content. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and not a full financial report or earnings release.
2020-10-29 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 21, 2020, by Moleculin Biotech, Inc. It primarily announces a press release about an independent study validating a drug's ability to target tumors. The document includes a press release as an exhibit and does not contain detailed financial statements or substantive financial data. The length is 3766 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. The document explicitly states that the information is being furnished and not filed, indicating it is an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2020-10-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 13, 2020, by Moleculin Biotech, Inc. It announces a press release about additional positive interim clinical trial results. The document includes a press release as Exhibit 99.1 and explicitly states that the information is furnished and not filed, indicating it is an announcement rather than a full report. The length is 3747 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial or management report. The content focuses on a press release disclosure under Regulation FD, which is typical for current reports on Form 8-K. Therefore, the document fits best into the Regulatory Filings (RNS) category, which is the fallback for miscellaneous SEC filings like Form 8-K current reports that do not fit other specific categories.
2020-10-13 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 2, 2020. The key content is the appointment of Elizabeth Cermak as an independent member of the Board of Directors, including details about her committee assignments and compensation. This clearly relates to changes in the company's board of directors. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy statement or voting results announcement. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3645 characters, which is typical for such announcements. Confidence is high due to explicit mention of director appointment and related details.
2020-10-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 6, 2020. It announces a press release about new antiviral drug candidates demonstrating in vitro activity against HIV, Zika, and Dengue Fever. The document includes a press release as an exhibit and explicitly states that the information is being furnished and not filed, indicating it is an announcement rather than a full report. The length is 3850 characters, which is relatively short and consistent with a regulatory announcement rather than a detailed financial or management report. There is no substantive financial data or detailed analysis present. Therefore, this document fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K announcements that do not fit other specific categories.
2020-10-06 English
FORM 4
Director's Dealing
2020-10-05 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.